February 27, 2018 / 6:46 AM / 3 months ago

BRIEF-Ose Immunotherapeutics To Resume Patient Accrual In U. S. For Phase 3 Tedopi Clinical Trial

Feb 27 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:

* OSE IMMUNOTHERAPEUTICS GRANTED APPROVAL TO RESUME PATIENT ACCRUAL IN U. S. FOR PHASE 3 TEDOPI CLINICAL TRIAL IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS FOLLOWING IMMUNE CHECKPOINT INHIBITOR TREATMENT

* TRIAL WILL BE CONDUCTED IN TWO STEPS

* PHASE 1: ENROLLMENT OF AROUND 100 PATIENTS AND PERFORMANCE ANALYSIS OF SURVIVAL DATA

* BASED ON PHASE 1 RESULTS WILL DETERMINE PHASE 2

* PRIMARY ENDPOINT OF TRIAL IS OVERALL SURVIVAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below